211 related articles for article (PubMed ID: 25421578)
1. Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.
Koh MY; Nguyen V; Lemos R; Darnay BG; Kiriakova G; Abdelmelek M; Ho TH; Karam J; Monzon FA; Jonasch E; Powis G
Cancer Res; 2015 Jan; 75(2):316-29. PubMed ID: 25421578
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.
Green YS; Sargis T; Reichert EC; Rudasi E; Fuja D; Jonasch E; Koh MY
Mol Cancer Res; 2019 May; 17(5):1220-1232. PubMed ID: 30705246
[TBL] [Abstract][Full Text] [Related]
3. The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.
Koh MY; Lemos R; Liu X; Powis G
Cancer Res; 2011 Jun; 71(11):4015-27. PubMed ID: 21512133
[TBL] [Abstract][Full Text] [Related]
4. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation.
Koh MY; Darnay BG; Powis G
Mol Cell Biol; 2008 Dec; 28(23):7081-95. PubMed ID: 18838541
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
[TBL] [Abstract][Full Text] [Related]
8. Targeting HIF2 in Clear Cell Renal Cell Carcinoma.
Cho H; Kaelin WG
Cold Spring Harb Symp Quant Biol; 2016; 81():113-121. PubMed ID: 27932568
[TBL] [Abstract][Full Text] [Related]
9. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
Lai XM; Liu SY; Tsai YT; Sun GH; Chang SY; Huang SM; Cha TL
Oncotarget; 2017 Jul; 8(30):49713-49724. PubMed ID: 28572533
[TBL] [Abstract][Full Text] [Related]
10. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
12. STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells.
Pawlus MR; Wang L; Hu CJ
Oncogene; 2014 Mar; 33(13):1670-9. PubMed ID: 23604114
[TBL] [Abstract][Full Text] [Related]
13. Upstream stimulatory factor 2 and hypoxia-inducible factor 2α (HIF2α) cooperatively activate HIF2 target genes during hypoxia.
Pawlus MR; Wang L; Ware K; Hu CJ
Mol Cell Biol; 2012 Nov; 32(22):4595-610. PubMed ID: 22966206
[TBL] [Abstract][Full Text] [Related]
14. STAT3 or USF2 contributes to HIF target gene specificity.
Pawlus MR; Wang L; Murakami A; Dai G; Hu CJ
PLoS One; 2013; 8(8):e72358. PubMed ID: 23991099
[TBL] [Abstract][Full Text] [Related]
15. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
17. Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response.
Pawlus MR; Hu CJ
Cell Signal; 2013 Sep; 25(9):1895-903. PubMed ID: 23707522
[TBL] [Abstract][Full Text] [Related]
18. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
19. Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.
Pasupuleti V; Du W; Gupta Y; Yeh IJ; Montano M; Magi-Galuzzi C; Welford SM
J Biol Chem; 2014 Feb; 289(6):3713-23. PubMed ID: 24356968
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S
J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
